Serum 25-hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men

Cancer

Volumn 123, Issue 14, 2017, Pages 2698-2704

  Layne, Tracy M ^a,b   Weinstein, Stephanie J ^b   Graubard, Barry I ^b   Ma, Xiaomei ^a,c   Mayne, Susan T ^a,c,d   Albanes, Demetrius ^b  

^a YALE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c YALE CANCER CENTER   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

25 hydroxyvitamin D; African American black men; prostate cancer; racial ethnic cancer disparities; vitamin D binding protein

Indexed keywords

25 HYDROXYVITAMIN D; VITAMIN D BINDING PROTEIN; 25-HYDROXYVITAMIN D; VITAMIN D;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; GLEASON SCORE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; VITAMIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; BLOOD; MIDDLE AGED; ODDS RATIO; PROSTATIC NEOPLASMS; RISK FACTOR; STATISTICAL MODEL; UNITED STATES;

AFRICAN AMERICANS; AGED; CASE-CONTROL STUDIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; UNITED STATES; VITAMIN D; VITAMIN D-BINDING PROTEIN;

EID: 85017467677     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30634     Document Type: Article

References (30)

1. Williams H, Powell IJ. Epidemiology, pathology, and genetics of prostate cancer among African Americans compared with other ethnicities. Methods Mol Biol. 2009;472:439–453.
2. DeSantis CE, Siegel RL, Sauer AG, et al. Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin. 2016;66:290–308.
3. Chornokur G, Dalton K, Borysova ME, Kumar NB. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate. 2011;71:985–997.
4. Freedman DM, Cahoon EK, Rajaraman P, et al. Sunlight and other determinants of circulating 25-hydroxyvitamin D levels in black and white participants in a nationwide US study. Am J Epidemiol. 2013;177:180–192.
5. Armas LA, Dowell S, Akhter M, et al. Ultraviolet-B radiation increases serum 25-hydroxyvitamin D levels: the effect of UVB dose and skin color. J Am Acad Dermatol. 2007;57:588–593.
6. Moore CE, Radcliffe JD, Liu Y. Vitamin D intakes of adults differ by income, gender and race/ethnicity in the USA, 2007 to 2010. Public Health Nutr. 2013:1–8.
7. Swami S, Krishnan AV, Feldman D. Vitamin D metabolism and action in the prostate: implications for health and disease. Mol Cell Endocrinol. 2011;347:61–69.
8. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–281.
9. Chun RF, Peercy BE, Orwoll ES, Nielson CM, Adams JS, Hewison M. Vitamin D and DBP: the free hormone hypothesis revisited. J Steroid Biochem Mol Biol. 2014;144:132–137.
10. Xu Y, Shao X, Yao Y, et al. Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis. J Cancer Res Clin Oncol. 2014;140:1465–1477.
11. Corder EH, Guess HA, Hulka BS, et al.: Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev. 1993;2:467–472.
12. Paller CJ, Kanaan YM, Beyene DA, et al. Risk of prostate cancer in African-American men: evidence of mixed effects of dietary quercetin by serum vitamin D status. Prostate. 2015;75:1376–1383.
13. Murphy AB, Nyame Y, Martin IK, et al. Vitamin D deficiency predicts prostate biopsy outcomes. Clin Cancer Res. 2014;20:2289–2299.
14. Steck SE, Arab L, Zhang H, et al. Association between plasma 25-hydroxyvitamin D, ancestry and aggressive prostate cancer among African Americans and European Americans in PCaP. PLoS One. 2015;10:e0125151.
15. Park SY, Cooney RV, Wilkens LR, Murphy SP, Henderson BE, Kolonel LN. Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic cohort. Eur J Cancer. 2010;46:932–936.
16. Kristal AR, Till C, Song X, et al. Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2014;23:1494–1504.
17. Jackson MD, Tulloch-Reid MK, Lindsay CM, et al. Both serum 25-hydroxyvitamin D and calcium levels may increase the risk of incident prostate cancer in Caribbean men of African ancestry. Cancer Med. 2015;4:925–935.
18. Black A, Huang WY, Wright P, et al. PLCO: Evolution of an epidemiologic resource and opportunities for future studies. Rev Recent Clin Trials. 2015;10:238–245.
19. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21(Suppl. 6):273S–309S.
20. Gallicchio L, Helzlsouer KJ, Chow WH, et al.: Circulating 25-hydroxyvitamin D and the risk of rarer cancers: Design and methods of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010;172:10–20.
21. Weinstein SJ, Stolzenberg-Solomon RZ, Kopp W, Rager H, Virtamo J, Albanes D. Impact of circulating vitamin D binding protein levels on the association between 25-hydroxyvitamin D and pancreatic cancer risk: a nested case-control study. Cancer Res. 2012;72:1190–1198.
22. Corder EH, Friedman GD, Vogelman JH, Orentreich N. Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men. Cancer Epidemiol Biomarkers Prev. 1995;4:655–659.
23. Ahn J, Peters U, Albanes D, et al. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst. 2008;100:796–804.
24. Gilbert R, Martin RM, Beynon R, et al.: Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose–response meta-analysis. Cancer Causes & Control. 2011;22:319–340.
25. Speeckaert MM, Speeckaert R, van Geel N, Delanghe JR. Vitamin D binding protein: a multifunctional protein of clinical importance. Adv Clin Chem. 2014;63:1–57.
26. Nagasawa H, Sasaki H, Uto Y, Kubo S, Hori H. Association of the macrophage activating factor (MAF) precursor activity with polymorphism in vitamin D-binding protein. Anticancer Res. 2004;24:3361–3366.
27. Kisker O, Onizuka S, Becker CM, et al. Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia. 2003;5:32–40.
28. Gregory KJ, Zhao B, Bielenberg DR, et al. Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells. PLoS One. 2010;5:e13428.
29. Weinstein SJ, Mondul AM, Kopp W, Rager H, Virtamo J, Albanes D. Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer. Int J Cancer. 2013;132:2940–2947.
30. Henderson CM, Lutsey PL, Misialek JR, et al. Measurement by a novel LC-MS/MS methodology reveals similar serum concentrations of vitamin D-binding protein in blacks and whites. Clin Chem. 2016;62:179–187.